{'fraction_non_alphanumeric': 0.028419182948490232, 'fraction_numerical': 0.0017761989342806395, 'mean_word_length': 5.409090909090909, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparison of testis cancer‐specific survival: an analysis of national cancer registry data from the USA, UK and Germany

While most testis cancer is curable, successful treatment entails prompt diagnosis, appropriate treatment and followup; therefore, access to the healthcare system is vital. Given low rates of insurance coverage among young men in the USA [1], we designed a registry-based study to compare population-level testis cancer-specific survival in the USA with two European countries that have widely available public insurance: the UK and Germany.